High levels of CTGF expression correlate positively with glioblastoma growth (57), invasive melanoma behavior (58), poor prognosis in esophageal adenocarcinoma (59), aggressive behavior of pancreatic cancer cells (60), and bone metastasis in breast cancer (61). The gene discussed is CCN2; the disease is melanoma.